A study by National Cheng Kung University Hospital in Taiwan analyzed 2,776 patients worldwide with diabetes, end-stage kidney disease and heart failure. Those using GLP-1 drugs had a 28% lower overall risk of heart attack, ischemic stroke, cardiac arrest or worsening heart failure than users of another class of glucose-lowering drugs.
Today's highlights
🌏 Regional Digest
🏷️ Topic Digest
🗞️ Latest news by region
Loading...
